Skip to main content
Erschienen in: World Journal of Surgery 1/2017

22.08.2016 | Original Scientific Report

Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer

verfasst von: Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Schmidt, Eliza Beal, Ioannis Hatzaras, Rivfka Shenoy, Shishir K. Maithel, Timothy M. Pawlik

Erschienen in: World Journal of Surgery | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

While surgery offers the best curative-intent treatment, many patients with biliary tract malignancies have poor long-term outcomes. We sought to apply a non-mixture cure model to calculate the cure fraction and the time to cure after surgery of patients with peri-hilar cholangiocarcinoma (PHCC) or gallbladder cancer (GBC).

Methods

Using the Extrahepatic Biliary Malignancy Consortium, 576 patients who underwent curative-intent surgery for gallbladder carcinoma or peri-hilar cholangiocarcinoma between 1998 and 2014 at 10 major hepatobiliary institutions were identified and included in the analysis. A non-mixture cure model was adopted to compare mortality after surgery to the mortality expected for the general population matched by sex and age.

Results

The median and 5-year overall survival (OS) were 1.9 years (IQR, 0.9–4.9) and 23.9 % (95 % CI, 19.6–28.6). Among all patients with PHCC or GBC, the probability of being cured after surgery was 14.5 % (95 % CI, 8.7–23.2); the time to cure was 9.7 years and the median survival of uncured patients was 1.8 years. Determinants of cure probabilities included lymph node metastasis and CA 19.9 level (p ≤ 0.05). The cure fraction for patients with a CA 19.9 < 50 U/ml and no lymph nodes metastases were 39.0 % versus only 5.1 % among patients with a CA 19.9 ≥ 50 who also had lymph node metastasis.

Conclusions

Examining an “all comer” cohort, <15 % of patients with PHCC or GBC could be considered cured after surgery. Factors such CA 19.9 level and lymph node metastasis independently predicted long-term outcome. Estimating the odds of statistical cure following surgery for biliary tract cancer can assist in decision-making as well as inform discussions around survivorship.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Valero V 3rd et al (2012) Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 6(4):481–495CrossRefPubMedPubMedCentral Valero V 3rd et al (2012) Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 6(4):481–495CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Hansel DE et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163(1):217–229CrossRefPubMedPubMedCentral Hansel DE et al (2003) Identification of novel cellular targets in biliary tract cancers using global gene expression technology. Am J Pathol 163(1):217–229CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed Valle J et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14):1273–1281CrossRefPubMed
6.
Zurück zum Zitat Friend E et al (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104(4):587–592CrossRefPubMedPubMedCentral Friend E et al (2011) Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21. Br J Cancer 104(4):587–592CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat El-Khoueiry AB et al (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30(4):1646–1651CrossRefPubMed El-Khoueiry AB et al (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30(4):1646–1651CrossRefPubMed
8.
Zurück zum Zitat El-Khoueiry AB et al (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110(4):882–887CrossRefPubMedPubMedCentral El-Khoueiry AB et al (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110(4):882–887CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Ben-Josef E et al (2015) SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622CrossRefPubMed Ben-Josef E et al (2015) SWOG S0809: a Phase II intergroup trial of adjuvant capecitabine and gemcitabine followed by radiotherapy and concurrent capecitabine in extrahepatic cholangiocarcinoma and gallbladder carcinoma. J Clin Oncol 33(24):2617–2622CrossRefPubMed
10.
Zurück zum Zitat Jarnagin WR et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–519) CrossRefPubMedPubMedCentral Jarnagin WR et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517 (discussion 517–519) CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Akamatsu N, Sugawara Y, Hashimoto D (2011) Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol 2(2):94–107CrossRefPubMedPubMedCentral Akamatsu N, Sugawara Y, Hashimoto D (2011) Surgical strategy for bile duct cancer: advances and current limitations. World J Clin Oncol 2(2):94–107CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Mao K et al (2016) Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 31(2):417–426CrossRefPubMedPubMedCentral Mao K et al (2016) Patterns and prognostic value of lymph node dissection for resected perihilar cholangiocarcinoma. J Gastroenterol Hepatol 31(2):417–426CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Wang J et al (2015) Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol 22(Suppl 3):1100–1106CrossRef Wang J et al (2015) Evaluation of adjuvant radiation therapy for resected gallbladder carcinoma: a multi-institutional experience. Ann Surg Oncol 22(Suppl 3):1100–1106CrossRef
14.
Zurück zum Zitat Hueman MT, Vollmer CM Jr, Pawlik TM (2009) Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16(8):2101–2115CrossRefPubMed Hueman MT, Vollmer CM Jr, Pawlik TM (2009) Evolving treatment strategies for gallbladder cancer. Ann Surg Oncol 16(8):2101–2115CrossRefPubMed
15.
Zurück zum Zitat Amini N et al (2015) Lymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems. J Surg Oncol 111(3):299–305CrossRefPubMed Amini N et al (2015) Lymph node status after resection for gallbladder adenocarcinoma: prognostic implications of different nodal staging/scoring systems. J Surg Oncol 111(3):299–305CrossRefPubMed
16.
Zurück zum Zitat Weiss MJ et al (2014) Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg 399(6):679–692CrossRefPubMed Weiss MJ et al (2014) Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg 399(6):679–692CrossRefPubMed
18.
Zurück zum Zitat Maetani S, Gamel JW (2010) Evolution of cancer survival analysis. Surg Oncol 19(2):49–51 (discussion 61) CrossRefPubMed Maetani S, Gamel JW (2010) Evolution of cancer survival analysis. Surg Oncol 19(2):49–51 (discussion 61) CrossRefPubMed
19.
Zurück zum Zitat Lambert PC et al (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8(3):576–594CrossRefPubMed Lambert PC et al (2007) Estimating and modeling the cure fraction in population-based cancer survival analysis. Biostatistics 8(3):576–594CrossRefPubMed
20.
Zurück zum Zitat Cvancarova M et al (2013) Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 132(7):1700–1710CrossRefPubMed Cvancarova M et al (2013) Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 132(7):1700–1710CrossRefPubMed
21.
Zurück zum Zitat Dal Maso L et al (2014) Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 25(11):2251–2260CrossRefPubMedPubMedCentral Dal Maso L et al (2014) Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818 902 Italian patients and 26 cancer types. Ann Oncol 25(11):2251–2260CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Spolverato G et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121(22):3998–4006CrossRefPubMed Spolverato G et al (2015) Can hepatic resection provide a long-term cure for patients with intrahepatic cholangiocarcinoma? Cancer 121(22):3998–4006CrossRefPubMed
23.
Zurück zum Zitat Edge SB, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd D, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New York
24.
Zurück zum Zitat Mayo SC et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) 13(7):473–482CrossRef Mayo SC et al (2011) Refining the definition of perioperative mortality following hepatectomy using death within 90 days as the standard criterion. HPB (Oxford) 13(7):473–482CrossRef
25.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240(2):205–213CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Tsodikov AD, Ibrahim JG, Yakovlev AY (2003) Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc 98(464):1063–1078CrossRefPubMedPubMedCentral Tsodikov AD, Ibrahim JG, Yakovlev AY (2003) Estimating cure rates from survival data: an alternative to two-component mixture models. J Am Stat Assoc 98(464):1063–1078CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Miyazaki M et al (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22(4):249–273CrossRefPubMed Miyazaki M et al (2015) Clinical practice guidelines for the management of biliary tract cancers 2015: the 2nd English edition. J Hepatobiliary Pancreat Sci 22(4):249–273CrossRefPubMed
30.
Zurück zum Zitat Chan E, Berlin J (2015) Biliary tract cancers: understudied and poorly understood. J Clin Oncol 33(16):1845–1848CrossRefPubMed Chan E, Berlin J (2015) Biliary tract cancers: understudied and poorly understood. J Clin Oncol 33(16):1845–1848CrossRefPubMed
31.
32.
Zurück zum Zitat Kim Y et al (2015) Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer 121(20):3564–3573CrossRefPubMedPubMedCentral Kim Y et al (2015) Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer. Cancer 121(20):3564–3573CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Pawlik TM et al (2014) What are patients’ expectations about the effects of chemotherapy for advanced cancer? J Am Coll Surg 219(3):588–590CrossRefPubMed Pawlik TM et al (2014) What are patients’ expectations about the effects of chemotherapy for advanced cancer? J Am Coll Surg 219(3):588–590CrossRefPubMed
34.
Zurück zum Zitat Cai C et al (2012) smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Progr Biomed 108(3):1255–1260CrossRef Cai C et al (2012) smcure: an R-package for estimating semiparametric mixture cure models. Comput Methods Progr Biomed 108(3):1255–1260CrossRef
35.
Zurück zum Zitat De Angelis R et al (1999) Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 18(4):441–454CrossRefPubMed De Angelis R et al (1999) Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 18(4):441–454CrossRefPubMed
36.
Zurück zum Zitat Cai WK et al (2014) Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol 7(11):7890–7898PubMedPubMedCentral Cai WK et al (2014) Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma. Int J Clin Exp Pathol 7(11):7890–7898PubMedPubMedCentral
38.
Zurück zum Zitat Goere D et al (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257(6):1065–1071CrossRefPubMed Goere D et al (2013) Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy? Ann Surg 257(6):1065–1071CrossRefPubMed
39.
Zurück zum Zitat Hosokawa I et al (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23(6):1897–1905CrossRefPubMed Hosokawa I et al (2016) Long-term survival benefit and potential for cure after R1 resection for colorectal liver metastases. Ann Surg Oncol 23(6):1897–1905CrossRefPubMed
40.
Zurück zum Zitat Rama R, Swaminathan R, Venkatesan P (2010) Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev 11(2):387–391PubMed Rama R, Swaminathan R, Venkatesan P (2010) Cure models for estimating hospital-based breast cancer survival. Asian Pac J Cancer Prev 11(2):387–391PubMed
Metadaten
Titel
Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer
verfasst von
Gaya Spolverato
Fabio Bagante
Cecilia G. Ethun
George Poultsides
Thuy Tran
Kamran Idrees
Chelsea A. Isom
Ryan C. Fields
Bradley Krasnick
Emily Winslow
Clifford Cho
Robert C. G. Martin
Charles R. Scoggins
Perry Shen
Harveshp D. Mogal
Carl Schmidt
Eliza Beal
Ioannis Hatzaras
Rivfka Shenoy
Shishir K. Maithel
Timothy M. Pawlik
Publikationsdatum
22.08.2016
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 1/2017
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-016-3691-y

Weitere Artikel der Ausgabe 1/2017

World Journal of Surgery 1/2017 Zur Ausgabe

Innovative Surgical Techniques Around the World

3D Printed Surgical Instruments: The Design and Fabrication Process

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.